Work

Metformin and Cancer: Is This the End?

Year: 2022

Type: article

Source: Endocrine Practice

DOI: 10.1016/j.eprac.2022.06.005

Authors: Emily J. Gallagher, Nathan G. Kase, Nina A. Bickell, Derek LeRoith

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Metabolism, Diabetes, and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Novartis, Icahn School of Medicine at Mount Sinai, National Institutes of Health, Department of Medicine, Georgetown University, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute on Minority Health and Health Disparities

Awards: G1493670431, ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center, Insulin Resistance and Breast Cancer Prognosis in Black & White Women, Cholesterol promotes breast cancer progression: establishing the mechanisms, Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer, G6806495283, Obesity and triple negative breast cancer; the role of hypercholesterolemia, Standardizing the Quality of Care in Ambulatory Practices, G945276084

OpenAlex ID: W4283068894

FWCI: 0.163

Cites: 14

Cited by: 2

Related to: 10